Cases & Deals

PTC Therapeutics develops global patent portfolio for small molecule therapeutics

Client(s) PTC THERAPEUTICS, INC.

Jones Day represents PTC Therapeutics, Inc. in the establishment of a global patent portfolio related to nonsense mutation suppressor TRANSLARNA® for the treatment of Duchenne Muscular Dystrophy ("DMD") and alternative splicing compounds for the treatment of Spinal Muscular Atrophy ("SMA").